-
Study Links Merck’s COVID-19 Antiviral Pill to Mutated Strains -
Top 5 US Pharma Companies Netted $82 Billion in 2022: Report
-
Johnson & Johnson Sues to Block Medicare Drug Price Negotiations
-
Merck Facing Lawsuits for Allegedly Hiding Severe Psychiatric Side Effects of Asthma Drug
-
Merck Sues Biden Administration Over ‘Sham’ Drug Price Negotiation Program
-
HPV Vaccine: Is It Even Worth It?
-
Merck’s COVID-19 Drug Fails to Show ‘Statistically Significant Reduction’ in Infection Risk
-
Researchers Link COVID-19 Drug to New Virus Mutations in Patients
-
Merck Opts to Develop, Sell Cancer Vaccine With Moderna
-
Merck’s Antiviral COVID-19 Pill Approved in Singapore
-
Merck Raises 2022 Forecast as COVID Pill, Cancer Drug Fuels Profit Beat
-
FDA Rejects Eli Lilly’s China-Developed Cancer Drug
-
Merck Sees 2022 Sales up Nearly 20 Percent, Mostly on New COVID Pill
-
EU Approves Pfizer’s COVID-19 Pill for Adults at Risk of Severe Disease
-
Researchers Concerned CCP Virus Will Develop Resistance to New Pfizer, Merck Pills
-
Merck Expects COVID-19 Pill Molnupiravir to Be Effective Against Omicron
-
Italy to Receive 40,000 Merck Antiviral Drug Doses Next Week: Official
-
Facts Matter (Jan. 7): Rejects FDA Request, Gives Agency 8 Months to Produce Pfizer’s Safety Data
-
India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns
-
Merck Authorizes Indian Pharma Company to Manufacture and Supply Affordable COVID-19 Pills
-
France Cancels Order for Merck’s COVID-19 Antiviral Drug
-
FDA Authorizes Merck’s COVID-19 Pill Weeks After US Makes $2.2 Billion Purchase
-
Denmark Approves Merck’s COVID-19 Antiviral Treatment in EU First
-
FDA Advisers Vote to Recommend Merck COVID-19 Pill for Emergency Use Authorization
-
New Analysis Shows Merck’s COVID-19 Antiviral Treatment Has Lower Efficacy
-
EU Recommends Merck COVID-19 Pill for Adults at Risk of Severe Illness
-
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
